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This	report	describes	the	development	of	an	aptamer	for	sensing	azole	
antifungal	drugs	for	therapeutic	drug	monitoring.		Modified	Synthetic	
Evolution	of	Ligands	through	Exponential	Enrichment	(SELEX)	was	used	
to	discover	a	DNA	aptamer	 recognizing	azole	 class	antifungal	drugs.	
This	aptamer	undergoes	a	secondary	structural	change	upon	binding	
to	 its	 target	 molecule	 as	 shown	 through	 fluorescence	 anisotropy-
based	 binding	 measurements.	 Experiments	 using	 circular	 dichroism	
spectroscopy,	revealed	a	unique	double	G-quadruplex	structure	that	
was	essential	and	specific	 for	binding	to	 the	azole	antifungal	 target.	
Aptamer-functionalized	 Graphene	 Field	 Effect	 Transistor	 (GFET)	
devices	were	created	and	used	to	measure	the	binding	of	strength	of	
azole	 antifungals	 to	 this	 surface.	 	 In	 total	 this	 aptamer	 and	 the	
supporting	 sensing	 platform	 could	 provide	 a	 valuable	 tool	 for	
improving	the	treatment	of	patients	with	invasive	fungal	infections.	
Understanding	 a	 drug’s	 pharmacokinetics	 is	 crucial	 to	 safely	 and	
effectively	treating	patients.	Unfortunately,	drug	levels	in	patients	can	
vary	 significantly,	 and	 the	 factors	 contributing	 to	 this	 variability	 are	
frequently	misunderstood.	For	some	critically-ill	patients,	it	is	essential	
to	gauge	levels	of	drug	in	real-time.		The	best	therapeutic	management	
can	 be	 achieved	 by	 maintaining	 a	 therapeutic	 level	 in	 a	 patient’s	
bloodstream	 and	 by	 optimizing	 individual	 dosage	 regimens.	 	 These	
analyses	generally	rely	upon	trough	and	peak	monitoring,	and	real-time	
kinetic	 drug	 modeling.	 For	 this	 reason,	 therapeutic	 drug	 monitoring	
(TDM)	of	some	drugs	is	a	critical	component	of	successful	therapy	(1).	It	
is	 particularly	 important	 to	 monitor	 drugs	 with	 narrow	 therapeutic	
ranges,	marked	pharmacokinetic	variability,	target	concentrations	that	
are	difficult	to	monitor,	and	drugs	known	to	cause	adverse	events.		
The	azole	antifungal	drugs	posaconazole,	fluconazole,	voriconazole,	and	
itraconazole,	 are	 an	 important	 class	 of	 lanosterol	 14α-demethylase	
enzyme	 inhibiting	 molecules	 (2),	 which	 compromise	 fungal	 cell	
membranes	 by	 preventing	 the	 synthesis	 of	 the	 key	 component	
ergosterol	(3).		A	number	of	these	drugs	are	highly	hydrophobic,	which	
creates	 analytical	 challenges.	 	 Furthermore,	 because	 of	 their	
hydrophobic	nature	it	is	difficult	to	know	how	much	of	the	drug	is	freely	
available	 in	 the	 blood	 at	 any	 given	 time.	 	 Wide	 variances	 in	 the	
pharmacokinetics	of	critically	ill	patients	have	been	observed	for	triazole	
drugs	like	voriconazole	and	posaconazole,	which	has	resulted	in	a	need	
for	TDM	(4).	 	Furthermore,	posaconazole	and	voriconazole	have	been	
shown	 to	 have	 drastically	 different	 bioavailability	 depending	 on	 how	
they	are	administered	and	if	they	are	co-administered	with	other	drugs	
(5,	 6).	 Therapeutic	 drug	 monitoring	 in	 conjunction	 with	 antifungal	
therapy	 has	 been	 shown	 to	 promote	 more	 favorable	 outcome	
compared	 to	 the	 non-TDM	 group	 (7).	 	 Unfortunately,	 TDM	 requires	
blood	to	be	drawn	from	patients	and	then	drug	levels	in	blood	evaluated	
by	analytical	 instrumentation,	 at	 some	 later	point	 in	 time.	 	Analytical	
techniques	using	machinery	such	as	Liquid	Chromatography	and	Mass	
Spectrometry	require	skilled	staff	and	resources	that	are	not	found	in	all	
hospitals	 (8).	 	 These	 barriers	 become	especially	 difficult	 to	 overcome	
when	treating	patients	in	community	hospitals,	at	home	or	in	resource	
limited	settings.		Effective	methods	for	sensing	small	drug	molecules	in	
blood	samples	would	make	it	easier	to	determine	drug	concentrations.			
Any	effective	TDM	method	requires	a	way	to	capture	 the	drug	target	
from	a	patient	sample.		Antibodies	provide	specificity	and	sensitivity	as	
a	capture	probe,	but	 they	are	 typically	unstable	over	a	wide	range	of	
assay	conditions.		As	a	more	robust	alternative,	oligonucleotide-based	
aptamer	 capture	 probes	 were	 developed	 as	 a	 stable	 and	 selective	
capture	molecule	for	small	molecule	drugs.		Oligonucloetide	aptamers	
can	bind	to	a	wide	variety	of	target	molecules	with	high	affinity.		Such	
oligonucleotides,	i.e.	DNA	and	RNA	libraries	of	1014-1016	molecules	can	
be	quickly	synthesized	and	screened	using	the	in	vitro	SELEX	(Synthetic	
Evolution	of	Ligands	through	Exponential	Enrichment)	methods	(9,	10).			
In	 this	 report,	 azole-specific	 aptamer	 were	 created,	 which	 bind	
posaconazole	 in	 its	 free	 form	 by	 using	 a	 modified	 SELEX	 method	 to	
screen	 a	 library	 of	 more	 than	 1014	 DNA	 sequences.	 Furthermore,	
Graphene	 Field	 Effect	 Transistors	 (GFETs)	 were	 developed	 as	 a	
biosensing	 platform	 for	 detecting	 azole	 antifungal	 drugs	 with	 these	
aptamers.		These	devices	represent	a	newly	emerging	type	of	biosensor	
that	relies	on	changes	in	current	and	gate	voltage	of	the	transistor	itself	
rather	than	the	flow	of	an	electrolyte	solution,	binding	of	antibodies,	or	
fluorescence	 labeling	 (11).	 Taken	 together	 these	 results	 provide	 a	
possible	path	 forward	for	development	of	an	azole	antifungal	sensing	
device	 with	 potential	 broader	 downstream	 capability	 of	 improving	
therapeutic	drug	monitoring	of	small	molecule	drugs.	
Results		
SELEX	Process	Results.	A	posaconazole-binding	aptamer	was	generated	
from	 a	 random	 40-mer	 library	 using	 a	modified	 SELEX	 process.	 	 PCR	
output	and	Oligreen	Dye	intensity	were	used	to	track	the	enrichment	of	
posaconazole	 binders.	 	 The	 output	 of	 the	 PCR	 experiments	 for	 each	
selection	round	was	plotted	after	15	and	25	cycles	of	PCR	amplification	
in	addition	to	the	intensity	of	Oligreen	dye	on	DNA	containing	counter	
SELEX	and	SELEX	(target)	beads	(	Fig.	1	A,B).		During	rounds	of	increased	
pressure	such	as	round	5	and	6,	the	total	PCR	output	decreases,	but	then	
recovers	 in	 later	 rounds.	 	 This	 is	 indicative	 of	 enrichment	 of	 target	
binding	aptamers.		Furthermore,	the	relative	amount	of	aptamer	bound	
to	 target	 beads	 versus	 control	 beads	 increases	 in	 later	 rounds.	 	 This	
becomes	especially	clear	past	Round	10	when	the	beads	are	first	washed	
with	the	competitive	molecule	fluconazole.		This	wash	allows	for	weak	
binding	molecules	to	be	eluted	from	the	sample.	
Denaturing	 polyacrylamide	 gels	 were	 used	 to	 assess	 whether	 or	 not	
their	molecular	weight	changed	during	SELEX.		Each	round	displays	two	
bands,	which	are	a	result	of	leftover	double	stranded	DNA	not	digested	
by	λ	exonuclease	(	Fig.	2A).		The	single	strand	bands	from	Rounds	1-10	
are	the	same	size	as	the	single	strand	control	library.		The	larger	bands	
from	Rounds	11,	12,	and	13	are	still	distinct	from	the	library	band	when	
denatured	 (	 Fig.	 2C).	 	 Each	 band	 was	 separated	 as	 described	 in	 the	
Methods	section	and	further	analyzed.				
Selection	of	Best	Consensus	Sequence.	After	separation,	the	“Heavy”	
and	 “Light”	 bands	 were	 analyzed	 separately	 for	 their	 binding	
capabilities.		The	Light	bands	of	Round	12	and	13,	those	the	same	length	
as	 the	 library,	 do	 not	 bind	 to	 the	 target	 (Fig.	 3).	 	 The	 Heavy	 bands,	
however,	bound	significantly	better	to	the	posaconazole	labeled	beads	
versus	the	control	beads	and	were	used	for	further	studies.			The	heavy	
Rd	13	 CGGGGGGAGGCGGAGGGAGGACTGGGGCTTCATTGAC
GTTCTTCACAGTAGGGGTAAGGGCTTAGGTGGTTGGTG
CCTG	
Rd	9	 CGCGGGGAGGAGGAGGCAGACTGGGGCTTCTTTGACG
TTC	
bands	 from	 Round	 13	 as	 well	 as	 the	 sample	 from	 Round	 9	 were	
sequenced.		
Table	2		
Here,	 red	 indicates	 overlap	 and	 yellow	 highlight	 shows	 regions	 of	
predicted	G-quadruplex	structure.		The	consensus	sequence	for	Rd	9	is	
the	same	size,	40	bases,	as	the	original	library.		The	consensus	sequence	
for	Rd	13	is	almost	double	that	size	at	79	bases.		A	significant	portion	of	
the	Rd	9	sequence,	in	red,	is	found	in	the	Rd	13	sequence.		Additionally,	
QGRS	 mapping	 was	 used	 to	 predict	 the	 existence	 of	 G-quadruplex	
structure	 in	 these	 sequences	 (12).	 	 The	 Rd	 9	 consensus	 sequence	
contains	one	predicted	G-quadruplex	stretch,	highlighted.		Interestingly,	
the	 Rd	 13	 sequence	 contains	 two	 regions	 of	 predicted	 G-quadruplex	
structure.		Stem-loop	structure	predicting	software	was	used	to	map	the	
room	temperature	(298	K)	structures	of	these	aptamers	(S2)	(13).		These	
predictions	 show	 that	while	Rd	9	 forms	 a	 stem-loop	 structure	with	 a	
single	 arm,	 Rd	 13	 has	 two	 separate	 arms.	 	 These	 features	 became	 a	
major	focus	of	the	further	study	of	these	aptamers.	
	
	
	
	
	
	
	
	
	
Fig.	1.	(A)	the	number	of	pmoles	of	PCR	output	after	each	round.			After	rounds	5	and	6	the	output	decreases	due	to	increased	pressure.		The	output	increases	in	later	
rounds	and	amplification	can	even	be	seen	after	only	15	cycles	of	PCR	as	opposed	to	25	cycles.		In	(B)	the	fluorescence	intensity	of	the	Oligreen	dye	from	aptamer	
samples	incubated	with	either	control	beads	or	posaconazole	(target)	 labeled	beads.	 	 In	later	rounds	the	amount	bound	to	the	target	beads	generally	increases	as	
binders	are	enriched
	
Control	 Sequences.	 This	 study	 included	 several	 control	 sequences	 to	
further	 investigate	 the	 importance	 of	 the	 structure	 of	 the	 Rd	 13	
aptamer:	Rd	13	Scrambled	(S),	Rd	13	T6	and	Rd	13	T1	were	created	with	
varying	middle	lengths.	
Table	3		
	
	
	
	
	
	
	
	
	
Fig.	 2	 After	 the	 addition	 of	 fluconazole	 there	 are	 bands	 that	 are	 higher	 in	
molecular	 weight	 than	 the	 starting	 library	 N	 and	 the	 original	 sequences.	 	 A	
denaturing	polyacrylamide	gel	(C)	highlights	the	fact	that	these	bands	are,	in	fact,	
unique	molecular	weight	 aptamers	 and	not	 aggregates	 of	 the	 smaller	 original	
library	sequence	N.	
Rd	13	Scrambled,	was	carefully	reordered	from	the	original	sequence	to	
fully	prevent	the	formation	of	G-quadruplex	structures.		The	two	other	
sequences	maintained	the	G-quadruplex	regions	but	with	two	different	
distances	between	them.			
	
	
	
	
	
	
	
	
	
Fig.	3	The	relative	binding	capabilities	of	the	heavy	and	light	bands	are	different	
to	Control	(Counter)	and	Target	(Posaconazole)	labeled	beads	respectively.		Light	
bands	from	Round	12	and	Round	13	showed	little	preference	for	either	type	of	
beads.	 	 The	 Heavy	 bands,	 however,	 bound	 significantly	 better	 to	 the	 target	
labeled	beads	as	compared	to	the	control	beads.	
Binding	 Affinity	 of	 Azole	 Drug	 Aptamers.	 	 Small	 molecule	 aptamers	
work	best	when	they	have	strong	binding	affinity	and	low	dissociation	
constants.	 	 Fluorescence	 anisotropy	 experiments	 were	 used	 to	
Rd	13	S	 GCTGTGTGCGTGAGTGGAGTGCGCGCGAGAGTGAGT
GCGGTGAGAGATTCGGTGTGCGTGTCGTGATGAATGC
GACCGG	
Rd	13	T6	 CGGGGGGAGGCGGAGGGAGGACTGGGGCTGTAGGG
GTAAGGGCTTAGGTGGTTGGTGCCTG	
Rd	13	T1	 CGGGGGGAGGCGGAGGGAGGACTGGGTGGGGTAAG
GGCTTAGGTGGTTGGTGCCTG	
determine	 the	 dissociation	 constants	 for	 the	 posaconazole-aptamer	
complex	 (14,	 15).	 	 In	 these	 experiments	 only	 the	 Round	 13	 aptamer	
caused	 an	 increase	 in	 anisotropy	 from	 titrations	 of	 a	 constant	 PosBD	
concentration	with	increasing	amounts	of	DNA	aptamers	(Fig.	5A).		The	
control	library	and	Rd	9	fail	to	bind	to	the	PosBD.		It	should	be	noted	that	
the	 control	 library	 contains	 the	 primer	 sequences,	 bringing	 the	 total	
length	to	86	nucleotides.		The	difference	in	molecular	weights	between	
Rd13	and	Rd9	is	not	the	sole	reason	for	their	difference	in	anisotropy.		
The	 same	 data	 can	 be	 generated	 by	 holding	 the	 DNA	 aptamer	
concentration	constant	and	titrating	with	increasing	amounts	of	PosBD	
(Fig.	5B).		The	dissociation	constants	for	each	experiment	are	2.7	±	1.2	
μM	and	0.98	±	0.18	μM,	respectively.		The	overall	dissociation	constant	
for	PosBD	might	be	weaker	than	that	of	posaconazole	given	the	fact	that	
the	latter	was	used	in	the	SELEX	process	and	not	PosBD.	The	differences	
in	anisotropy	changes	were	further	used	to	probe	the	specificity	of	the	
aptamer	for	the	target.		Specificity	was	interrogated	with	respect	to	two	
other	 BODIPY	 labeled	 molecules:	 Isavuconazole	 (ISV),	 which	 is	
chemically	 similar	 to	 posaconazole,	 and	 caspofungin	 (CSF),	 which	 is	
chemically	dissimilar	since	it	is	an	echinocandin	class	drug.		Titrating	100	
pmoles	of	Rd	13	aptamer	into	a	125	μL	solution	containing	100	pmoles	
of	 PosBD	 causes	 a	 greater	 anisotropy	 change	 than	 titrating	 into	 100	
pmoles	of	ISV_BD	or	CF_BD	(Fig.	6).		Titrating	Rd9	or	the	Library	into	100	
pmoles	of	PosBD	causes	little	to	no	change	in	anisotropy.		The	truncated	
versions	T6	and	T1	cause	less	of	an	anisotropy	change,	though	Rd13	T6	
is	not	significantly	different	(Fig.	6	B).		The	Rd	13	scrambled	aptamer	did	
not	cause	a	significant	anisotropy	change	compared	to	a	control	such	as	
EDTA	and	hence	did	not	bind	to	PosBD.		These	results	indicated	that	the	
G-quadruplex	structure	is	necessary	for	binding.	
	
	
	
	
	
	
	
	
Fig.	5	The	anisotropy	changes	when	aptamer	was	titrated	into	a	100	pmoles/125	μL	of	PosBD.		The	anisotropy	changes	neither	with	the	earlier	round	(Rd	9)	nor	with	
the	control	library.		(B)	data	from	titrations	of	1000	pmoles	Rd13	in	125	μL	modified	SELEX	buffer	with	increasing	amounts	of	PosBD.		The	dissociation	constants	from	
each	experiment	were	calculated	to	be	2.7	±	1.2	μM	and	0.98	±	0.18	μM	respectively.						
	
	
	
	
	
	
	
	
Fig.	6	100	pmoles	of	aptamer	(Rd	13,	Rd	9,	or	the	Library)	were	titrated	into	100	pmoles	of	varioius	BODIPY	labeled	drugs	(Posaconazole	(Pos),	Isavuconazole	ISV),	and	
Caspofungin	(CSF)	(A).		Titrating	Rd	13	into	PosBD	caused	a	significant	change	in	anisotropy.		Titrating	Rd	13	into	other	BODIPY	labeled	drugs	or	Rd	9/Library	into	PosBD	
caused	little	changes	in	anisotropy.		These	data	suggest	that	Rd	13	binds	best	to	Posaconazole.		Different	length	aptamers	were	titrated	into	100	pmoles	of	PosBD	(B).		
The	full	length	Rd	13	aptamer	caused	the	greatest	change	in	anisotropy	and	the	truncated	and	scrambled	versions	showed	decreased	amounts	of	anisotropy	change.		
The	scrambled	version	only	caused	a	change	proportional	to	that	caused	by	a	chelator,	EDTA.
Binding	Competition	Assay.		The	aptamers	developed	in	this	study	bind	
to	 azole	 class	 antifungal	 drug	 targets,	 specifically	 to	 those	 with	 the	
exposed	 terminal	 azole	 group	 like	 posaconazole.	 	 High	 specificity	 is	
important	for	downstream	diagnostic	devices	to	prevent	false	positive	
readings.		The	anisotropy	experiments	were	modified	slightly	to	develop	
a	 competitive	 assay	 to	 further	 probe	 specificity.	 	 This	 experiment	
showed	 the	 relative	 ability	 of	 various	 drugs	 to	 replace	 PosBD	 in	 the	
aptamer	 complex	 (Fig.	 7).	 	 As	 expected,	 Posaconazole	 displaces	 the	
greatest	amount	of	PosBD.		Related	drugs	Fluconazole	and	Itraconazole	
replace	fewer	PosBD	molecules.	 	The	chemically	distinct	Echinocandin	
antifungal	drugs	Micafungin	and	Caspofungin	had	 little	effect.	 	Of	 the	
azole	drugs,	Itraconazole	is	the	most	hydrophobic.		The	lower	amount	
of	PosBD	 replacement	with	 Itraconazole	 versus	Posaconazole	 suggest	
that	 binding	 is	 not	 solely	 driven	 by	 hydrophobic	 effects.	 	 Secondary	
structure	 plays	 a	 large	 part	 in	 the	 binding	 of	 azole	 targets	 to	 these	
aptamers.	
		
	
	
	
	
	
	
	
	
Fig.	7	A	50	pmole/125	μL	solution	of	PosBD	was	incubated	with	1000	pmoles	of	
Rd	 13	 aptamer.	 	 After	 equilibration	 the	 aptamer	 was	 heated	 at	 70C	 in	 the	
presence	 of	 Posaconazole	 (Pos),	 Fluconazole	 (Flu),	 Itraconazole	 (Itra),	
Voriconizole	(Vori),	Micofungin	(MF),	or	Caspofungin	(CSF)	and	then	cooled	on	
ice.		The	percent	replaced	was	calculated	as	a	function	of	the	loss	in	anisotropy.	
Circular	 Dichroism	 and	 Secondary	 Structure	 Analysis.	 	 Secondary	
structure	controls	the	complexing	of	aptamers	and	target	molecules.	As	
these	 aptamers	 all	 contained	multiple	 stretches	 of	 guanine	 residues,	
there	is	a	high	possibility	that	they	form	G-quadruplex	structures.	 	CD	
Spectroscopy	experiments	were	conducted	to	probe	the	folding	of	these	
aptamers	in	the	presence	of	salts	and	posaconazole.		The	CD	spectra	of	
Rd13	are	characteristic	of	G-quadruplex	folded	DNA	with	a	maximum	at	
260	 nm	 and	 a	 minimum	 at	 240	 nm	 (Fig.	 8	 A)	 (16,	 17).	 	 Addition	 of	
magnesium	chloride	to	the	solution	both	increases	the	signal	at	260	nm	
and	decreases	 the	 signal	 at	 240	nm.	 	 This	 suggests	 that	 the	 aptamer	
forms	 a	 G-quadruplex	 structure	 in	 low	 salt	 buffer,	 which	 is	 slightly	
enhanced	with	the	addition	of	salts.		In	contrast,	the	signal	is	not	altered	
significantly	by	adding	posaconazole	in	the	absence	of	divalent	salts	(Fig.	
8	B).		The	most	drastic	change	occurs	when	the	aptamers	are	exposed	
to	a	combination	of	both	posaconazole	and	salts.	 	The	aptamers	Rd	9	
and	Rd	13	show	similar	CD	signals	in	0.2	mM	magnesium	chloride.		A	G-
quadruplex	structure	formed	with	Rd	9	and	Rd	13	but	not	with	Rd	13	
scrambled	(Fig.	8	C).	 	When	100	μM	posaconazole	was	added	there	is	
change	 in	 the	CD	 signal	 for	Rd	9	and	Rd	13.	 	With	posaconazole,	 the	
spectra	for	Rd	9	changes	to	contain	a	maximum	at	230	nm	and	a	drastic	
minimum	at	280	nm	 (Fig.	 8	D).	 	 The	 spectra	 for	Rd	13	 in	magnesium	
chloride	with	posaconazole	contains	two	maximum	at	about	230	nm	and	
270	nm	with	a	minimum	above	300	nm.		The	Rd	13	scrambled	sequence	
does	not	undergo	any	 further	change	 in	 secondary	structure.	 	 The	G-
quadruplex	structure	of	Rd	13	forms	in	the	presence	of	salt	and	that	this	
structure	then	changes	when	the	target	is	added.		
	
	
	
	
	
	
	
	
	
Fig.	 8	 Addition	 of	 magnesium	 chloride	 to	 the	 Rd	 13	 aptamer	 enhances	 G-
qudruplex	folding	(A)	but	addition	of	posazonazole	does	not	(B).		This	is	seen	in	
an	increase	in	the	maximum	at	260	nm	and	a	decrease	in	the	minimum	at	240	
nm.	Both	Rd	13	and	Rd	9	exhibit	G-quadruplex	structure	in	0.2	mM	Magnesium	
chloride	salt	(C).		The	structure	changes	drastically	in	the	presence	of	magnesium	
chloride	and	100	μM	posaconazole	(D).		The	Rd	13	scrambled	aptamer	does	not	
change	but	Rd	9	now	contains	a	peak	230	nm	and	a	minimum	at	280	nm	and	Rd	
13	contains	two	peaks	at	230	nm	and	260	nm	with	a	new	minimum	peak	above	
300	nm	
Graphene	Field	Effect	Transistors.		When	incorporated	with	Graphene	
Field	 Effect	 transistors,	 these	 aptamers	 act	 in	 an	 induced-fit	manner,	
which	allows	 them	 to	 function	as	 a	 small	molecule	 capture	arm	on	a	
supported	surface.		GFET	devices	functionalized	with	amino-Rd13	were	
used	to	measure	Posaconazole	concentration	(Fig.	9).		Posaconazole	was	
diluted	 from	 DMSO	 into	 SELEX	 buffer	 as	 described	 above.	 	 As	
concentrations	of	Posaconazole	were	increased	from	0.01	μg/mL	to	100	
μg/mL,	the	gate	threshold	voltage	shift	increased	to	upwards	of	-6V.		In	
contrast,	treatment	with	the	echinocandin	drug	Caspofungin	produced	
a	negligible	shift	in	the	gate	threshold	voltage.		These	values	are	in	the	
range	of	was	has	been	seeing	with	antibody-functionalized	biosensing	
devices	and	a	related	biosensor	for	HIV	drugs(18,	19).		Interestingly,	the	
aptamers	on	these	devices	were	shown	to	have	a	dissociation	constant	
of	1.8	±	0.5	μg/mL	or	approximately	1.8	μM.		These	values	are	in	good	
agreement	with	the	dissociation	constant	derived	from	the	anisotropy	
assay.	 	 These	data	 suggest	 that	 support	 functionalized	Rd13	aptamer	
binds	posaconazole	in	a	similar	fashion	to	free	Rd13	aptamer.	
	
	
	
	
	
	
	
	
	
	
Fig.	9	Data	of	 the	response	of	Rd13	 functionalized	GFET	devices	 to	azole	class	
drug	 Posaconazole	 and	 echinocandin	 class	 drug	 Caspofungin.	 	 The	 devices	
showed	a	detectable	threshold,	Dirac	Voltage	shift	between	0.1	mg/mL	and	0.1	
μg/mL.		These	values,	especially	the	low	μg/mL	range	are	therapeutically	relevant	
concentrations	 of	 azole	 class	 antifungal	 drugs.	 	 Notably,	 even	 at	 the	 highest	
concentration,	0.1	mg/mL	caspofungin	caused	no	detectable	response	above	the	
background,	indicating	specificity	for	azole	antifungal	drugs.			
Discussion			
Therapeutic	drug	monitoring	requires	a	method	of	capturing	molecules	
and	separating	them	from	a	sample	for	analysis.	This	report	highlights	
the	development	of	a	drug	capturing	oligonucleotide	using	our	SELEX	
process	and	the	discovery	of	a	unique	structure,	which	allows	it	to	bind	
azole	 antifungal	 drugs.	 	 Circular	 Dichroism	 spectrophotometry	 shows	
that	 this	 oligonucleotide	works	 as	 a	 scaffold	with	 two	 sections	 of	 G-
quadruplex	 folds.	 	 Large	 protein	 target	 aptamers	 have	 been	 made	
before	using	two,	separate	G-quadruplexes	linked	chemically	to	bind	at	
separate	 sites	 (20).	 	 These	 types	 of	 folds	 rarely	 interact	with	 smaller	
hydrophobic	molecules	due	to	the	highly	charged	nature	of	single	strand	
DNA.	 The	 Rd13	 aptamer	 was	 generated	 as	 a	 result	 of	 single	 G-
quadruplex	aptamers	of	this	library	interacting	directly.		These	are	not	
simple	stem-loop	structures	found	 in	most	SELEX	assays.	 	 Instead	this	
library	 and	 SELEX	 process	 managed	 to	 access	 potential	 quaternary	
structures	by	overlapping	G-quadruplexes.	 	When	 the	 target	binds	 to	
these	 aptamers	 the	 quaternary	 structure	 can	 transform	 from	
overlapping	G-quadruplex	 to	 another	 structure	 similar	 to	 a	B->Z	DNA	
transition(21,	 22).	 	 This	 transition	 can	 play	 a	 role	 in	 developing	
downstream	applications.	
This	 type	 of	 dual	 G-quadruplex	 aptamer	 is	 ideal	 for	 capturing	 small	
hydrophobic	molecules.		The	anisotropy	binding	experiments	show	that	
the	G-quadruplex	 is	essential	 for	 target	binding.	 	When	bound	 to	 the	
surface	of	a	Graphene	Field	Effect	Transistor,	 the	aptamer	works	as	a	
capture	arm.	 	This	arm	collects	posaconazole	 from	the	sample,	which	
leads	to	a	change	in	the	GFET	gate	voltage.		The	azole	“aptasensor”	adds	
to	the	list	of	other	aptamer-based	sensing	devices	(23,	24).		Unlike	these	
other	devices,	however,	GFET	aptamer	biosensors	have	the	potential	to	
function	without	 the	need	 for	 secondary	antibodies,	 fluorophores,	or	
electrochemical	 mediators.	 	 The	 versatility	 of	 oligonucleotide	 based	
biosensor	opens	the	door	to	numerous	different	applications.	
Taken	 together,	 the	 unique	 structure	 and	 binding	 properties	 of	
Oligonucleotide	provided	with	the	sensitivity	of	Graphene	Field	Effect	
Transistors	 could	 prove	 useful	 for	 therapeutic	 drug	 monitoring.		
Posaconazole	and	the	other	azole	class	antifungal	drugs	exhibit	strong	
hydrophobicity	 and	 protein	 binding.	 	 Despite	 this	 fact,	 this	 aptamer	
binds	 specifically	 to	 azole	 drugs.	 	 There	 are	 other	 aptamers	 towards	
clinically	interesting	drugs	as	well	such	as	the	Aminoglycoside	Antibiotics	
and	 Antiretroviral	 Drugs	 among	 others(25,	 26).	 	 The	work	 presented	
here	 provides	 the	 first	 basic	 step	 towards	 effective	 Therapeutic	Drug	
Monitoring:	a	method	of	capturing	and	sensing	the	drug.		These	other	
aptamers	could	also	be	utilized	as	capture	arms	for	a	graphene-based	
sensing	platform.		The	next	step	will	involve	testing	patient	samples	and	
validating	their	usefulness	in	clinic.		Such	a	devices	will	allow	clinicians	
to	quickly	assess	azole	concentrations	in	a	patient’s	blood	and	to	provide	
them	with	the	additional	care	that	they	need.	
Materials	and	Methods	
N40	DNA	Aptamer	library	was	purchased	from	Tri-link	Biotechnologies	
Inc	 (Ronkonkoma,	 NY).	 	 Other	 oligonucleotides	 including	 amino-
functionalized	oligonucleotides	were	synthesized	by	IDT	(Coralville,	IA),	
Sigma-Aldrich	(St.	Louis,	MO)	and	Biosearch	Technologies	(Novato,	CA).		
Carboxyl	Dynabeads	(14305D),	Oligreen	ssDNA	assay	kit,	and	BODIPY	FL	
Dye	 were	 purchased	 from	 Life	 Technologies	 Co	 (Carlsbad,	 CA).		
Streptavidin	magnetic	beads	and	Lamda	Exonuclease	were	purchased	
from	New	England	Biolabs	(Boston,	MA).		Azole	Drugs	were	purchased	
from	 Santa	 Cruz	 Biotechnologies	 (Dallas,	 TX).	 	 All	 other	 reagents	 and	
solvents	were	purchased	from	Thermo	Fisher	Scientific	(Waltham,	MA).	
Graphene	devices	were	fabricated	in-house	using	methods	described	in	
previous	work(11)	
SELEX	 Process.	 The	 aptamer	 library	 from	 Trilink	 Biotechnologies	 was	
prepared	by	dissolving	1	nmol	of	DNA	in	100	μL	of	SELEX	buffer	(140	mM	
Sodium	Chloride,	2	mM	Potassium	Chloride,	5	mM	Magnesium	Chloride,	
2	mM	Calcium	Chloride,	0.05%	Tween	in	20	mM	pH	7.4	Tris	Buffer).	The	
library	was	heated	at	94°C	for	3	minutes,	placed	on	ice	for	5	minutes,	
and	then	incubated	at	room	temperature	(25°C)	for	5	minutes.	Next,	the	
DNA	 library	 was	 incubated	 for	 1	 hour	 at	 50°C	 and	 2	 hours	 at	 room	
temperature,	then	in	later	rounds	10	minutes	at	50°C	and	20	minutes	at	
room	temperature.		For	the	first	round,	the	library	was	incubated	with	
1	mg	of	unlabeled	carboxyl	dynabeads	(counter	SELEX).		The	beads	were	
carefully	concentrated	using	a	magnet.		The	library	was	then	incubated	
with	1	mg	of	posaconazole	labeled	beads	for	1	hour	at	50°C	and	2	hours	
at	 room	 temperature.	 	 The	 beads	were	washed	 3	 times	with	 100	 μL	
SELEX	buffer	and	1	time	with	100	μL	Millipore	water	incubated	with	1	
nmol	posaconazole	in	20uL	of	water	with	0.01%	DMSO	for	1	hour.		The	
recovered	DNA	was	purified	using	a	Zymo	Research	DNA	preparation	
columns.	 Recovered	 DNA	 was	 amplified	 in	 two	 Polymerase	 Chain	
Reaction	(PCR)	conditions.		First,	the	20	μL	of	DNA	was	amplified	using	a	
Takara	rTaq	DNA	polymerase	enzyme.		The	mixture	contained,	2.5	μL	of	
(10	 μM)	 Forward	 Primer,	 2.5	 μL	 of	 (10	 μM)	 Phosphorylated	 Reverse	
Primer,	5	μL	of	2.5mM	dNTPs,	5μL	of	10X	MgCl2	buffer,	0.5	μL	(2.5	units)	
of	 rTaq	 Enzyme,	 20	 μL	 DNA	 and	 14.5	 μL	 Millipore	 water.	 PCR	 was	
performed	with	the	following	conditions:	94°C	5	minutes	initial	then	15	
cycles	of	94°C	for	30	seconds,	50°C	for	30	seconds	and	72°C	for	1	minute	
followed	by	a	final	5	minutes	of	extension	at	72°C.		This	sample	was	then	
treated	as-is	with	1	μL	(5	units)	of	λ	Exonuclease	and	incubated	at	37°C	
for	30	minutes.		This	mixture	was	purified	using	a	Zymo	columns	and	the	
output	 was	 checked	 for	 absorbance	 at	 260	 nanometers	 using	 a	
Nanodrop	 spectrophotometer.	 	 If	 the	 yield	 was	 less	 than	 1pmol	 an	
additional	PCR	was	conducted	as	above	but	substituting	10	cycles	 for	
the	 15	 cycles.	 Further	 rounds	 of	 SELEX	 included	 the	 following	
modifications:		For	round	2	through	5,	200	pmoles	capacity	beads	were	
used	 instead	 of	 1	 nmoles.	 	 After	 round	 5,	 incubation	 times	 were	
decreased	 to	30	min	 counter	 SELEX,	 then	10	minutes	 at	 50°C	and	20	
minutes	 at	 room	 temperature.	 	 After	 round	 6	 the	 bead	 capacity	was	
decreased	to	20	pmoles.		In	rounds	11	to	13	beads	were	incubated	for	1	
hour	 with	 1	 μL	 of	 1M	 Fluconazole	 in	 20	 μL	 first	 as	 an	 additional	
competitive	wash	before	washing	with	Posaconazole.	(S1)	
SELEX	Results	Tracking.	 	In	each	round	1	μL	of	DNA-incubated	control	
beads	 and	 1	 μL	 of	 DNA-incubated	 posaconazole	 labeled	 beads	 were	
saved	after	washing	with	water	but	before	posaconazole	elution.		The	
DNA	content	was	assessed	using	a	1:800	solution	of	Oligreen	dye	in	20	
mM	Tris	buffer	with	2	mM	EDTA	at	pH	7.5		The	sample	were	analyzed	
using	a	Photon	Technology	International	(PTI)	Fluorometer.		PCR	output	
was	measured	 using	 a	 Nanodrop	 Spectrophotometer.	 	 DNA	 size	 was	
investigated	by	running	an	8%	polyacrylamide	gel	and	denaturing	gels	
were	run	using	8%	polyacrylamide	gel	with	8	M	Urea	in	SDS	buffer	after	
loading	DNA	treated	with	formamide	at	100	°C.		Sequencing	of	various	
rounds	was	performed	by	Macrogen	(Rockville,	MD)	to	determine	the	
consensus	sequence	for	that	round.	
Fluorescence	 Binding	 Experiments.	 	 Purified	 bands	 and	 synthesized	
consensus	sequences	were	prepared	by	taking	2	pmoles	and	dissolving	
them	in	100	μL	SELEX	buffer.		These	solutions	were	heated	at	94°C	for	3	
minutes,	on	ice	for	5	minutes,	and	at	room	temperature	for	5	minutes.		
The	 samples	 were	 incubated	 with	 20	 pmol	 capacity	 posaconazole	
labeled	 and	 unlabeled	 beads	 at	 50°C	 for	 10	 minutes	 and	 room	
temperature	for	20	minutes.	 	The	samples	were	then	washed	2	times	
with	 water	 and	 125	 μL	 of	 a	 1:800	 dilution	 Oligreen	 Dye	 was	 added.		
Samples	 were	 then	 heated	 at	 94°C	 for	 3	 minutes,	 the	 beads	 were	
concentrated,	and	the	supernatant	was	collected.		Samples	were	excited	
at	 480	 nm	 with	 emission	 scanning	 from	 500	 nm	 to	 550	 nm.	 	 The	
fluorescence	was	recorded	as	CPS	at	520	minus	the	CPS	at	505	nm.	
Fluorescence	 Anisotropy	 Binding	 Experiments.	 	 Fluorescence	
Anisotropy	experiments	were	conducted	using	a	PTI	Fluorometer	with	
Fluorescence	Polarizers.		One	hundred		pmoles	of	Posaconazole	BODIPY	
(PosBD)	was	added	from	DMSO	(1	μL)	to	125	μL	of	modified	SELEX	buffer	
(140	mM	Sodium	Chloride,	2	mM	Potassium	Chloride,	5	mM	Magnesium	
Chloride,	 2	 mM	 Calcium	 chloride,	 in	 20	 mM	 pH	 7.4	 Tris	 Buffer)(12).		
Fluorescence	anisotropy	experiments	were	 recorded	using	a	polarizer	
system	 and	 the	 G-factor	 was	 calculated	 manually	 for	 each	 run	 but	
consistently	 fell	 within	 0.44-0.45.	 	 Anisotropy	 measurements	 were	
recorded	 first	 for	 2	minutes.	 	 After	 the	 initial	 2	 minutes,	 aliquots	 of	
aptamers	from	1	pmoles	to	2000	pmoles	were	added,	and	samples	were	
equilibrated	for	5	minutes.		The	value	of	the	anisotropy	was	taken	to	be	
the	 average	 anisotropy	 of	 the	 last	 60	 seconds	 after	 equilibration.		
Anisotropy	values	were	plotted	as	the	change	in	anisotropy:	
Equation	1:	∆ 𝑟 (𝐶) = 𝑟 (𝐶) − 𝑟 (		
These	values	were	used	to	calculate	a	bound	fraction:	
Equation	2:	𝐹*(+,-(𝐶) = ∆ . (/)∆ . 012	
The	bound	fraction	was	further	used	to	calculate	a	dissociation	constant	
by	fitting	to:	
Equation	3:	𝐹*(+,- 𝐶 = //345	
Fluorescence	 Anisotropy	 Competition	 Assays.	 	 Competition	 assays	
were	performed	using	the	same	measurement	techniques	as	described	
above	for	binding	assays.		In	this	experiment,	50	pmoles	of	PosBD	was	
added	 from	 DMSO	 into	 125	 μL	 of	 modified	 SELEX	 buffer,	 and	 the	
anisotropy	 was	 recorded	 for	 2	 minutes.	 One	 thousand	 pmoles	 of	
aptamer	was	 then	 added	 and	 allowed	 to	 equilibrate	 for	 10	minutes.		
After	this	time,	1000	pmoles	of	an	unlabeled	drug	molecule	was	added	
and	the	solution	was	heated	up	to	70oC	for	3	minutes	and	cooled	on	ice	
for	2	minutes.		The	heat-ice	cycle	was	performed	twice.		The	anisotropy	
was	then	recorded	again	for	another	5	minutes.		The	percent	of	PosBD	
replaced	was	calculated	as:	
Equation	4:	%	𝑅𝑒𝑝𝑙𝑎𝑐𝑒𝑑 = 100 ∗ . 1BC10DE,5EGHI . J. 1BC10DEI . J 	
Percent	replaced	equals	100	multiplied	by	the	anisotropy	with	aptamer	
and	 drug	 replacement	 minus	 the	 initial	 anisotropy	 divided	 by	 the	
anisotropy	caused	by	the	aptamer	alone	minus	the	initial	anisotropy	
Circular	Dichroism	Experiments.		Experiments	were	performed	using	an	
Aviv	 Model	 420	 CD	 Spectrophotometer.	 	 All	 aptamer	 samples	 were	
prepared	 at	 10	 μM	 concentration	 in	 20	 mM	 Tris	 buffer	 pH	 7.4.		
Increasing	amounts	of	salts	and/or	azole	antifungal	drugs	were	added	
and	the	CD	spectra	was	recorded	from	300	nm	to	200	nm.	
Graphene	 Field	 Effect	 Transistors	 Functionalization	 and	 Testing.	
Chemical	Vapor	Deposition	(CVD)	method	with	a	methane	source	was	
used	to	grow	graphene,	which	was	then	transferred	via	electrolysis	onto	
a	patterned	Si/SiO2	surface.		This	surface	contained	chromium	and	gold	
electrodes	 and	 the	 graphene	 channels	 between	 them	 were	 further	
defined	through	photolithography	and	annealed	in	an	argon/hydrogen	
environment.	 	 In	 order	 to	 functionalize	 the	 surface,	 GFETs	 were	
incubated	in	1-Pyrenebutyric	acid	N-hydroxysuccinimide	ester	(P-base)	
and	DMF	for	20	hours.		After	this	incubation,	the	devices	were	further	
incubated	in	a	solution	of	PBS	(pH	7.6)	containing	the	Rd13	aptamer	for	
3	 hours.	 	 The	 devices	 were	 heated	 from	 70oC	 to	 90oC,	 held	 at	 this	
temperature	 for	15	minutes,	and	then	allowed	to	cool	down	to	room	
temperature.		In	order	to	test	the	devices,	the	I-Vg	properties	of	GFETs	
were	measured	dry	pre-	and	post-incubation	with	either	the	azole	drug	
posaconazole	or	the	echinocandin	drug	caspofungin.
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